OBI-3424 (TH-3424) 是一种前药，可通过 AKR1C3 (醛基酮还原酶 1C3) 选择性地转化为有效的 DNA 烷基化剂。OBI-3424 可用于肝细胞癌，去势抵抗性前列腺癌和急性淋巴细胞白血病 (ALL) 的研究。
货号:ajcx33846
CAS:2097713-68-1
分子式:C21H25N4O6P
分子量：460.42
溶解度:DMSO : 50 mg/mL (108.60 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

OBI-3424 (TH-3424) is a prodrug that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. OBI-3424 can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research[1].

OBI-3424 exerts potent cytotoxicity against the H460 lung cancer cell line (IC50 of 4.0 nM). OBI-3424 exhibits potent cytotoxicity, in particular against cell lines derived from T-ALL with high AKR1C3 expression, with IC50 values in the low nM range[1].OBI-3424 also exerts potent cell killing against ALL PDXs, and the median IC50 values were 60.3 nM for B-ALL, 9.7 nM for T-ALL and 31.5 nM for ETP-ALL[1].

OBI-3424 (0.5-2.5 mg/kg; i.p.; once weekly; for 3 weeks) treatment induces regressions in PDXs mice and results in prolongation of mouse event-free survival[1].

[1]. Kathryn Evans, et al. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503.